Theriva Biologics Balance Sheet Health
Financial Health criteria checks 5/6
Theriva Biologics has a total shareholder equity of $39.7M and total debt of $225.0K, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are $55.2M and $15.5M respectively.
Key information
0.6%
Debt to equity ratio
US$225.00k
Debt
| Interest coverage ratio | n/a |
| Cash | US$23.18m |
| Equity | US$39.70m |
| Total liabilities | US$15.52m |
| Total assets | US$55.22m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: TOVX's short term assets ($27.4M) exceed its short term liabilities ($6.7M).
Long Term Liabilities: TOVX's short term assets ($27.4M) exceed its long term liabilities ($8.8M).
Debt to Equity History and Analysis
Debt Level: TOVX has more cash than its total debt.
Reducing Debt: TOVX's debt to equity ratio has increased from 0% to 0.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TOVX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TOVX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 0.3% each year.